A clever modification of surface sugars may turn mesenchymal stem cells (MSCs) into an effective weapon against osteoporosis.
MSCs can rebuild bone, but when injected into the bloodstream they lack the navigational tools to reach the skeleton. A recent Phase 1 clinical trial shows that an enzymatic cell-surface modification that directs MSC straight to bone marrow is safe and produces encouraging restorative signals (Cell 2026, DOI: 10.1016/j.cell.2026.08.017). Yet bone specialists caution that it is too early to claim clinical efficacy.
